An international group of scientists has called for a global moratorium on gene-edited babies; proposed guidance would limit the sale of flavored e-cigarettes; and the Senate has invited executives from 5 pharmacy benefit managers (PBMs) to testify at a hearing on drug prices.
Months after the controversial births of the world's first gene-edited babies, a group of 18 researchers from around the globe are calling for a world-wide moratorium on editing DNA in human sperm, eggs, and embryos, reported The Wall Street Journal. The researchers, who include some inventors of CRISPR, said that a moratorium would prevent irresponsible use of the technology before it causes irreversible changes.As part of the FDA’s ongoing effort to combat teen vaping, Commissioner Scott Gottlieb, MD, introduced proposed guidance that would limit the sale of flavored e-cigarettes to vape shops that bar sales to minors. The changes would not apply to menthol, mint, and tobacco flavors. According to The Hill, the proposal would likely ban sales of e-cigarettes at gas stations and convenience stores.The Senate Finance Committee has invited 5 executives from PBMs to its third drug pricing hearing on April 3. According to Reuters, Committee Chair Senator Chuck Grassley, R-Iowa, and Senator Ron Wyden, D-Oregon, invited executives from UnitedHealth Group’s OptumRx Cigna, Humana, CVS Caremark, and Prime Therapeutics to testify on rising prescription drug prices.
Contributor: More Informed Management of Preeclampsia Is Necessary
November 29th 2023At present, it is difficult for clinicians to identify patients at greatest risk for developing preeclampsia with severe features and tailor treatment plans for them; this difficulty increases costs significantly.
Read More
Untangling Medical Debt From Credit Scores: Effects So Far and Next Steps
November 29th 2023After recent policy changes removing most medical debts from credit reports, Americans are seeing their credit scores increase, but experts warn of the need to monitor billing and collection practices for unintended consequences.
Read More
Managed Care Cast Presents: Opportunities for Adalimumab Biosimilars, Part 1
November 10th 2023In part 1 of this 2-part podcast, a panel of experts discusses the provider and payer considerations for transitioning patients to biosimilars, approaches to prescribing biosimilars over reference products, and more.
Listen
Study Validates Smartphone Analysis for Predicting Obstructive Sleep Apnea
November 29th 2023Findings show breathing sounds recorded by smartphones during sleep at home can reliably identify obstructive sleep apnea, presenting an innovative and accessible alternative to traditional in-laboratory polysomnography.
Read More